# High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes

**Authors:** Mairene Coto-Llerena, Caner Ercan, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Serenella Eppenberger-Castori, Savas D. Soysal, Charlotte K. Y. Ng, Martin Bolli, Markus von Flüe, Guillaume P. Nicolas, Luigi M. Terracciano, Melpomeni Fani, Salvatore Piscuoglio

PMC · DOI: 10.3389/fonc.2020.00979 · Frontiers in Oncology · 2020-07-08

## TL;DR

High FAP levels in colorectal cancer are linked to aggressive tumor growth, poor survival, and changes in immune cell activity.

## Contribution

This study identifies FAP as a novel prognostic marker in colorectal cancer related to angiogenesis and immunoregulation.

## Key findings

- FAP is upregulated in CRC at both mRNA and protein levels and correlates with advanced stages and poor survival.
- High FAP expression is associated with an immunosuppressive tumor microenvironment and specific immune cell populations.
- FAP overexpression correlates with angiogenesis, collagen degradation, and regulatory T cell enrichment.

## Abstract

Fibroblast activation protein α (FAP) plays an important role in tissue remodeling and helps tumor cells invade surrounding tissue. We sought to investigate FAP as a prognostic molecular marker in colorectal cancer (CRC) using immunohistochemical and transcriptomic data. FAP expression and clinicopathological information were obtained from The Cancer Genome Atlas data set. The association of FAP expression and tissue cellular heterogeneity landscape was explored using the xCell method. We evaluated FAP protein expression in a cohort of 92 CRCs and 19 non-tumoral tissues. We observed that FAP was upregulated in tumors both at the mRNA and protein levels, and its expression was associated with advanced stages, poor survival, and consensus molecular subtype 4. FAP expression was also associated with angiogenesis and collagen degradation. We observed an enrichment in immune-cell process–related genes associated with FAP overexpression. Colorectal cancers with high FAP expression display an inflamed phenotype enriched for macrophages and monocytes. Those tumors showed enrichment for regulatory T cell populations and depletion of TH1 and natural killer T cells, pointing to an immunosuppressive environment. Colorectal cancers with high levels of stromal FAP are associated with aggressive disease progression and survival. Our results suggest that FAP plays additional roles in tumor progression such as modulation of angiogenesis and immunoregulation in the tumor microenvironment.

## Linked entities

- **Genes:** FAP (fibroblast activation protein alpha) [NCBI Gene 2191]
- **Proteins:** FAP (fibroblast activation protein alpha)
- **Diseases:** colorectal cancer (MONDO:0005575), CRC (MONDO:0005575)

## Full-text entities

- **Genes:** MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, KLRG1 (killer cell lectin like receptor G1) [NCBI Gene 10219] {aka 2F1, CLEC15A, MAFA, MAFA-2F1, MAFA-L, MAFA-LIKE}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}, NT5E (5'-nucleotidase ecto) [NCBI Gene 4907] {aka CALJA, CD73, E5NT, NT, NT5, NTE}, DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, MSH6 (mutS homolog 6) [NCBI Gene 2956] {aka GTBP, GTMBP, HNPCC5, HSAP, LYNCH5, MMRCS3}, CD276 (CD276 molecule) [NCBI Gene 80381] {aka 4Ig-B7-H3, B7-H3, B7H3, B7RP-2}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, FAP (fibroblast activation protein alpha) [NCBI Gene 2191] {aka DPPIV, FAPA, FAPalpha, SIMP}, SLC44A4 (solute carrier family 44 member 4) [NCBI Gene 80736] {aka C6orf29, CTL4, DFNA72, NG22, TPPT, hTPPT1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ICOS (inducible T cell costimulator) [NCBI Gene 29851] {aka AILIM, CD278, CVID1}, MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}
- **Diseases:** Ascending colon (MESH:D003108), Lymphovascular invasion (MESH:D009361), epithelial tumors (MESH:D002277), inflammation (MESH:D007249), metastasis (MESH:D009362), tumorigenesis (MESH:D063646), necrosis (MESH:D009336), fibrosis (MESH:D005355), CMS4 tumors (MESH:D009369), breast cancer (MESH:D001943), TMA (MESH:D017695), Colorectal Tumors (MESH:D015179), rectal cancer (MESH:D012004), Lymphatic invasion (MESH:D008207), venous (MESH:D014647)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC7362758/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7362758/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC7362758/full.md

---
Source: https://tomesphere.com/paper/PMC7362758